This series on “ALK and ROS-1 NSCLC patients treatment approach based on genomic profile by liquid biopsy” is edited by Dr. Jesús Corral, Dr. Laura Mezquita, and Dr. Ernest Nadal.
Jesús Corral, MD
Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, Spain
Dr. Corral graduated with Master Degree from Seville Medical School in 2003. He obtained his Medical Oncology degree at the University Hospital Virgen del Rocío, Seville (Spain) with an observership at M.D. Anderson Cancer Center, Houston (USA). He completed his career with a fellowship at Drug Development Unit from the Royal Marsden Hospital in London (UK) and a Master in Biomedical Research and Clinical Trials.
He is actually a Consultant in Medical Oncology (Thoracic Cancer Uni) at Clínica Universidad de Navarra, Madrid (Spain) and an associate professor of Universidad San Pablo CEU, Madrid (Spain). He has also been an active member of the Spanish Society of Medical Oncology (SEOM-Executive Comitee +MIR Section), the European Society of Medical Oncology (ESMO-Executive Comitee YOC Section), the Spanish Comission of Medical Oncology (Ministry of Health) and the Spanish Lung Cancer Cooperative Group (GECP).
He is author of more than 45 high impact factor journal papers, 14 books and 70 national/international meeting abstracts, focused on thoracic malignancies diagnosis and treatment.
Laura Mezquita, MD, PhD
Department of Medical Oncology, Hospital Clinic, Barcelona, Spain
Dr. Laura Mezquita is a Spanish medical oncologist, working in Thoracic Oncology. She finished her training in medical oncology in Salamanca in 2011, and then moved to Madrid where she worked for 4 years. Between 2015 and 2020 She has been working in Gustave Roussy (France) with Prof. Benjamin Besse as her mentor, initially as Translational Research Fellow in Lung Cancer ImmunoOncology (2015-2016), followed by a 2 years period of Clinical Fellow in the Thoracic Oncology Group (2016-2018). In November 2018, she joined the Precision Medicine Group. In 2018, She completed her PhD project about the impact of Radon gas in lung cancer. From February 2020, she has been working in the Thoracic Unit, at Hospital Clinic (Barcelona, Spain), and she has also joined the Translational Genomics and Targeted Therapeutics Group (IDIBAPS, Barcelona), as PostDoctoral Researcher. She is involved in several clinical and translational research projects focus on three main areas: a) biomarkers for immunotherapy, b) precision medicine, focus on the clinical utility of liquid biopsy in lung cancer, and c) molecular epidemiology (radon gas in lung cancer).
Ernest Nadal, MD, PhD
- Head of the Section of Thoracic Tumors, Department of Medical Oncology, Catalan Institute of Oncology, L’Hospitalet, Barcelona, Spain
- Assistant Professor, University of Barcelona, Department of Clinical Sciences, Campus Bellvitge, L’Hospitalet, Barcelona, Spain
- Principal Investigator of the Clinical Research in Solid Tumors (CReST) group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L’Hospitalet, Barcelona, Spain
Ernest Nadal obtained his MD degree in 2001 at the University of Valencia (Spain) and completed his training in Medical Oncology in 2006 at the Catalan Institute of Oncology (Barcelona, Spain). He completed his training in translational research at the University of Michigan (Ann Arbor, US) and returned to the Catalan Institute of Oncology in 2014 where he leads the research in Thoracic Tumors. He is an Associate Professor of Oncology since 2019 at the University of Barcelona.
The main research interests are the development of clinical trials in special populations of patients with thoracic malignancies, the study of novel therapeutic strategies in malignant pleural mesothelioma, the characterization of the immune contexture of brain metastases and the genomic characterization of early onset lung cancer patients. He published more than 50 papers including papers in high impact journals in the field of oncology or cancer biology.
- ALK NSCLC patients treatment approach
- ROS-1 NSCLC patients treatment approach
- (crizo/2nd generation) ALK NSCLC therapy resistance mechanisms
- (3rd generation) ALK NSCLC therapy resistance mechanisms
- ROS-1 NSCLC therapy resistance mechanisms
- Role of liquid biopsy in ALK/ROS-1treatment sequence
- An example of ALK NSCLC sequence of treatment
- An example of ROS-1 NSCLC sequence of treatment
- Future directions in ALK/ROS-1NSCLC population
- CNS progression and liquid biopsy in oncogene addicted tumors among patients treated by ALK/ROS-1
- Monitoring Therapeutic Response and Resistance with Liquid Biopsy
- Other biological fluids as a source of ctDNA to detect ALK/ROS1 fusions
The series “ALK and ROS-1 NSCLC patients treatment approach based on genomic profile by liquid biopsy” was commissioned by the editorial office, Precision Cancer Medicine without any sponsorship or funding. Jesús Corral, Laura Mezquita, and Ernest Nadal are serving as the unpaid Guest Editors for the series.